quiz bu lëkkale ak tegtal · Diggante Niveau

IA ci jàngat klinik

Xoolaat ni IA di jàppale méngoo malaad yi, nafar gëstu, jàngat yu méngoo, saytu kaaraange, ak gëmloo sàrt yi ci gëstu klinik yi.

Yooni njiit yu jëm ciIA ci test klinik
Laaj 1 de 8

Ban jafe-jafe bu yàgg ci test klinik yi IA di gëna xëcc?

Xoolaatal laaj bu nekk8 laaj

Sooy def quiz bi, tontu yi ak leeral yi dañuy feeñ.

  1. Ban jafe-jafe bu yàgg ci test klinik yi IA di gëna xëcc?
    • Recrutement malade bu yeex te jafe
    • Kulòoru emballage garab yi
    • Alluwa cafeteriu lopitaal bi
    • Gaaraas yi am ci barabi jàngat yi
  2. How can natural-language processing help screen patients for clinical trials?
    • Soo sànnee jàngat kaaraange
    • Extract clinical information from electronic health records and compare it with trial eligibility criteria
    • Sooy fay malaad yi lu ëpp say konkurër
    • Ni ñu wàññi àtte bi ci benn bis
  3. What is an external control arm in a clinical trial?
    • Benn tànk buñ defaree robot
    • Benn molecule drog buñ defaree ordinatër
    • A comparison group drawn from data outside the trial, such as historical or concurrent external data
    • Serveur de données sauvegarde
  4. What can propensity-score matching do when constructing an external-control comparison?
    • Tànneef ci alfabet
    • Defar nimero yu bari kese
    • Saytu ortograafi
    • Balance measured baseline covariates related to treatment assignment
  5. Lan moo waral xeetu bàyyi njàng mi ñuy wax luy am solo ci parrain yi?
    • Dañu may parrain yi ñu dugg ci balaa àtte bi di tàmbali
    • Ñoom ñooy jëmmal tabax bi
    • ñooy bind slogan yi
    • Dañuy tànn yéere liggéeykat yi
  6. What does FDA’s January 2025 draft AI guidance address for drugs and biologics?
    • Ngir yeexal bépp gëstu ba fàww
    • AI used to generate information supporting regulatory decisions about safety, effectiveness, or quality
    • Ndax IA jagul ci medsin
    • Ngir wàññi limu doktër yi
  7. What can a Bayesian adaptive clinical-trial design change as evidence accumulates?
    • The original trial question after results are known
    • The identity of past participants
    • Trial elements such as dosing or allocation to study arms under prespecified rules
    • The inclusion criteria without documentation
  8. Which pharmacovigilance tasks does FDA identify as possible uses for emerging AI?
    • Only advertising click-through rates
    • Satellite images of clinical sites
    • Unrelated social-media sentiment about packaging
    • Adverse-event intake, data entry, processing, and safety-signal detection or evaluation